uniQURE Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy QURE?
Source: Businesswire
- Lawsuit Background: Kirby McInerney LLP has announced a class action lawsuit on behalf of investors who acquired uniQURE N.V. securities between September 24, 2025, and October 31, 2025, alleging that the company failed to fully disclose FDA approval of its Pivotal Study design, potentially leading to investor losses.
- Stock Price Plunge: Following the disclosure on November 3, 2025, that the timeline for the BLA submission was unclear, uniQURE's stock price plummeted by $33.40, or approximately 49.33%, from $67.69 on October 31, 2025, reflecting strong market concerns about the company's future prospects.
- Investor Rights: Any investor who purchased shares during the class period can seek appointment as lead plaintiff in the class action lawsuit, with courts typically appointing those with the largest financial losses, ensuring that investor rights are protected throughout the legal process.
- Legal Consultation Opportunity: Kirby McInerney LLP offers no-cost legal consultations, encouraging affected investors to reach out to understand their rights and interests, indicating the firm's commitment to securing compensation for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 49.88 USD with a low forecast of 33.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.710
Low
33.00
Averages
49.88
High
70.00
Current: 24.710
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Class Action Lawsuit Reminder for Investors
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against uniQure N.V. for violations of the Securities Exchange Act, concerning securities purchased between September 24, 2025, and October 31, 2025, with a deadline for participation set for April 13, 2026.
- False Statements Allegation: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, which resulted in significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- BLA Timeline Delays: uniQure is accused of misleading the market regarding its ability to submit a Biologics License Application (BLA) on time, indicating potential delays to supplement data submitted to the FDA, which directly undermined investor confidence.
- Investor Losses: As the market learned the truth about uniQure, investors faced substantial losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for compensation, reflecting serious issues regarding the company's transparency and compliance.
See More
uniQURE Faces Class Action Lawsuit
- Lawsuit Background: Kirby McInerney LLP has announced a class action lawsuit on behalf of investors who acquired uniQURE N.V. securities between September 24, 2025, and October 31, 2025, alleging that the company failed to fully disclose FDA approval of its Pivotal Study design, potentially leading to investor losses.
- Stock Price Plunge: Following the disclosure on November 3, 2025, that the timeline for the BLA submission was unclear, uniQURE's stock price plummeted by $33.40, or approximately 49.33%, from $67.69 on October 31, 2025, reflecting strong market concerns about the company's future prospects.
- Investor Rights: Any investor who purchased shares during the class period can seek appointment as lead plaintiff in the class action lawsuit, with courts typically appointing those with the largest financial losses, ensuring that investor rights are protected throughout the legal process.
- Legal Consultation Opportunity: Kirby McInerney LLP offers no-cost legal consultations, encouraging affected investors to reach out to understand their rights and interests, indicating the firm's commitment to securing compensation for investors.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Class Action Filed: Kessler Topaz Meltzer & Check, LLP has initiated a securities fraud class action against uniQure, covering investors from September 24 to October 31, 2025, highlighting serious concerns regarding the company's transparency and compliance.
- Stock Price Volatility: On September 24, 2025, uniQure's stock surged from $13.66 to $47.50, a nearly 250% increase, but plummeted 49% to $34.29 on November 3, 2025, after the FDA withdrew its support for the clinical trial data, reflecting extreme market anxiety about the company's prospects.
- FDA Review Uncertainty: On November 3, 2025, uniQure admitted that the timeline for its BLA submission had become unclear due to the FDA's stance, leading to investor doubts about AMT-130's future and potentially impacting the company's financing and market confidence.
- Investor Rights Protection: Investors may seek to be appointed as lead plaintiffs in the class action by April 13, 2026, indicating a focus on corporate governance and transparency, which could influence future legal and financial outcomes.
See More
uniQure Faces Securities Class Action Investigation
- Investigation Launched: Faruq & Faruq LLP is investigating potential claims against uniQure N.V., reminding investors to apply for lead plaintiff status by April 13, 2026, indicating significant legal risks that may undermine shareholder confidence.
- FDA Approval Issues: The complaint alleges that uniQure's pivotal study design was not fully approved by the FDA, and the company failed to disclose this information adequately, leading to investor misconceptions about the company's future prospects and potentially affecting its ability to raise funds.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by 49%, from $67.69 to $34.29, after the FDA stated it no longer agreed that the data would support a BLA submission, reflecting strong market concerns about the company's future and potential severe investor losses.
- Legal Implications: The lead plaintiff will oversee the litigation, and any potential recovery will impact all shareholders, highlighting that deficiencies in corporate governance and transparency could lead to broader legal and financial repercussions.
See More
uniQure Accused of Misleading Investors Over FDA Approval
- Class Action Filed: Robbins LLP has initiated a class action on behalf of investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24, 2025, and October 31, 2025, alleging misleading statements regarding the likelihood of FDA approval, potentially leading to significant investor losses.
- FDA Feedback Impact: On November 3, 2025, uniQure disclosed that the FDA indicated its AMT-130 clinical trial data may not provide adequate primary evidence for BLA submission, resulting in a stock price drop of $33.40, or over 49%, from $67.69 to $34.29.
- Study Design Issues: The complaint highlights that uniQure failed to disclose that the design of its pivotal study was not fully approved by the FDA, and downplayed the need for additional studies to support its BLA submission, further damaging the company's credibility.
- Investor Rights Protection: Investors can apply to be lead plaintiffs in the class action by April 7, 2026, with Robbins LLP offering representation on a contingency fee basis, aiming to help investors recover losses and improve corporate governance practices.
See More
uniQure Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against uniQure in the Southern District of New York on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that uniQure made materially false and misleading statements during the class period and failed to disclose adverse facts about its business and operations, potentially leading to investor losses.
- FDA Approval Issues: The lawsuit highlights that the design of uniQure's pivotal study was not fully approved by the FDA, and the company may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, impacting its market outlook.
- Investor Rights Protection: Investors must apply by April 13, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations aimed at protecting investor rights.
See More
uniQure Faces Class Action Lawsuit Reminder for Investors
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against uniQure N.V. for violations of the Securities Exchange Act, concerning securities purchased between September 24, 2025, and October 31, 2025, with a deadline for participation set for April 13, 2026.
- False Statements Allegation: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, which resulted in significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- BLA Timeline Delays: uniQure is accused of misleading the market regarding its ability to submit a Biologics License Application (BLA) on time, indicating potential delays to supplement data submitted to the FDA, which directly undermined investor confidence.
- Investor Losses: As the market learned the truth about uniQure, investors faced substantial losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for compensation, reflecting serious issues regarding the company's transparency and compliance.
See More
uniQURE Faces Class Action Lawsuit
- Lawsuit Background: Kirby McInerney LLP has announced a class action lawsuit on behalf of investors who acquired uniQURE N.V. securities between September 24, 2025, and October 31, 2025, alleging that the company failed to fully disclose FDA approval of its Pivotal Study design, potentially leading to investor losses.
- Stock Price Plunge: Following the disclosure on November 3, 2025, that the timeline for the BLA submission was unclear, uniQURE's stock price plummeted by $33.40, or approximately 49.33%, from $67.69 on October 31, 2025, reflecting strong market concerns about the company's future prospects.
- Investor Rights: Any investor who purchased shares during the class period can seek appointment as lead plaintiff in the class action lawsuit, with courts typically appointing those with the largest financial losses, ensuring that investor rights are protected throughout the legal process.
- Legal Consultation Opportunity: Kirby McInerney LLP offers no-cost legal consultations, encouraging affected investors to reach out to understand their rights and interests, indicating the firm's commitment to securing compensation for investors.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Class Action Filed: Kessler Topaz Meltzer & Check, LLP has initiated a securities fraud class action against uniQure, covering investors from September 24 to October 31, 2025, highlighting serious concerns regarding the company's transparency and compliance.
- Stock Price Volatility: On September 24, 2025, uniQure's stock surged from $13.66 to $47.50, a nearly 250% increase, but plummeted 49% to $34.29 on November 3, 2025, after the FDA withdrew its support for the clinical trial data, reflecting extreme market anxiety about the company's prospects.
- FDA Review Uncertainty: On November 3, 2025, uniQure admitted that the timeline for its BLA submission had become unclear due to the FDA's stance, leading to investor doubts about AMT-130's future and potentially impacting the company's financing and market confidence.
- Investor Rights Protection: Investors may seek to be appointed as lead plaintiffs in the class action by April 13, 2026, indicating a focus on corporate governance and transparency, which could influence future legal and financial outcomes.
See More
uniQure Faces Securities Class Action Investigation
- Investigation Launched: Faruq & Faruq LLP is investigating potential claims against uniQure N.V., reminding investors to apply for lead plaintiff status by April 13, 2026, indicating significant legal risks that may undermine shareholder confidence.
- FDA Approval Issues: The complaint alleges that uniQure's pivotal study design was not fully approved by the FDA, and the company failed to disclose this information adequately, leading to investor misconceptions about the company's future prospects and potentially affecting its ability to raise funds.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by 49%, from $67.69 to $34.29, after the FDA stated it no longer agreed that the data would support a BLA submission, reflecting strong market concerns about the company's future and potential severe investor losses.
- Legal Implications: The lead plaintiff will oversee the litigation, and any potential recovery will impact all shareholders, highlighting that deficiencies in corporate governance and transparency could lead to broader legal and financial repercussions.
See More
uniQure Accused of Misleading Investors Over FDA Approval
- Class Action Filed: Robbins LLP has initiated a class action on behalf of investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24, 2025, and October 31, 2025, alleging misleading statements regarding the likelihood of FDA approval, potentially leading to significant investor losses.
- FDA Feedback Impact: On November 3, 2025, uniQure disclosed that the FDA indicated its AMT-130 clinical trial data may not provide adequate primary evidence for BLA submission, resulting in a stock price drop of $33.40, or over 49%, from $67.69 to $34.29.
- Study Design Issues: The complaint highlights that uniQure failed to disclose that the design of its pivotal study was not fully approved by the FDA, and downplayed the need for additional studies to support its BLA submission, further damaging the company's credibility.
- Investor Rights Protection: Investors can apply to be lead plaintiffs in the class action by April 7, 2026, with Robbins LLP offering representation on a contingency fee basis, aiming to help investors recover losses and improve corporate governance practices.
See More
uniQure Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against uniQure in the Southern District of New York on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that uniQure made materially false and misleading statements during the class period and failed to disclose adverse facts about its business and operations, potentially leading to investor losses.
- FDA Approval Issues: The lawsuit highlights that the design of uniQure's pivotal study was not fully approved by the FDA, and the company may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, impacting its market outlook.
- Investor Rights Protection: Investors must apply by April 13, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations aimed at protecting investor rights.
See More
